市場調查報告書
商品編碼
927773
冠狀動脈疾病治療的全球市場:成長,趨勢,預測(2020年~2025年)Coronary Artery Disease Therapeutics Market - Growth, Trends, and Forecasts (2022 - 2027) |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
全球冠狀動脈疾病治療市場在2020年~2025年的預測期間內預計將以5.5%的年複合成長率增長。冠狀動脈疾病(CAD),也稱為缺血性心臟疾病(IHD)及冠狀動脈心臟疾病(CHD),是一種由脂肪物質和斑塊在冠狀動脈中積聚引起冠狀動脈狹窄或阻塞的疾病。隨著全球性高血壓,高膽固醇,糖尿病和肥胖症的發病率和患病率增加,政府為提高對疾病的認識和加大對研發活動的投資的努力是冠狀動脈疾病治療市場上主要推動要素。
本報告提供全球冠狀動脈疾病治療市場的相關調查,提供市場機會和趨勢,成長及阻礙因素,各市場區隔和各地區的市場分析,競爭情形,主要企業的簡介等資訊。
The Coronary Artery Disease Therapeutics Market is expected to register a CAGR of 5.5% during the forecast period. Coronary Artery Disease (CAD) also known as ischemic heart disease (IHD) and coronary heart diseases (CHD) is a disease in which there is a narrowing or blockage of the coronary arteries due to buildup of fatty material and plaque inside the coronary arteries. These fatty material and plaque can restrict blood flow to the heart muscle by physically clogging the artery or by causing abnormal artery tone and function. Without an adequate blood supply to the heart, the heart becomes starved of oxygen which may cause chest pain (angina), shortness of breath, or other coronary artery disease signs and symptoms. A complete blockage can cause a heart attack. Coronary artery disease is thought to begin with injury or damage to the inner layer of a coronary artery. Damage may be caused by various factors, such as Smoking, Sedentary lifestyle, diabetes or insulin resistance, high blood pressure and high cholesterol. Some of the risk factors for coronary artery disease include age, sex, family history, obesity, and high stress among others.
According to the World Heart Federation, Coronary heart disease is now the leading cause of death worldwide. An estimated 3.8 million men and 3.4 million women die each year from coronary heart disease. In addition, 80% of the deaths occur in low- and middle-income countries.
Growing incidence and prevalence rate of hypertension, high cholesterol, diabetes, and obesity across the world, government initiatives to increase the awareness toward disease and increasing investment on research and development activity are the key driving factors in coronary artery disease therapeutics market.
North America is expected to hold a major market share in the global coronary artery disease therapeutics market due to the growing geriatric population, and increasing incidences of chronic diseases. According to the Centers for Disease Control and Prevention, in the year 2017, coronary heart disease is the most common type of heart disease, killing approximately 365,914 people in the United States. Moreover, about 18.2 million adults age 20 and older have Coronary heart disease (CAD). Furthermore, high healthcare spending and presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.
The Coronary Artery Disease Therapeutics Market is fragmented competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are AstraZeneca Plc, Gilead Sciences, Inc, Novartis AG, Pfizer Inc, Bayer AG, Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Merck & Co., Inc, Teva Pharmaceutical Industries Ltd and Mylan N.V.